OTCMKTS:SHTDF Sinopharm Group (SHTDF) Stock Price, News & Analysis → Gold Set to EXPLODE! (From Gold Safe Exchange) (Ad) Free SHTDF Stock Alerts $2.70 0.00 (0.00%) (As of 06/14/2024 ET) Add Compare Share Share Today's Range$2.70▼$2.7050-Day Range$2.46▼$2.9452-Week Range$2.30▼$3.46VolumeN/AAverage Volume4,376 shsMarket CapitalizationN/AP/E Ratio2.71Dividend Yield9.63%Price TargetN/A Stock AnalysisStock AnalysisChartFinancialsShort InterestStock AnalysisChartFinancialsShort Interest Get Sinopharm Group alerts: Email Address Ad Traders AgencyHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942%, and 12,592% in 2020. Now their next one could be here.Click here to pay just $5 for a full year of Stealth Trades About Sinopharm Group Stock (OTCMKTS:SHTDF)Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People's Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical products to hospitals, other distributors, retail pharmacy stores, and clinics. This segment also offers distribution, logistics, and other value-added services for domestic and international pharmaceutical and healthcare products manufacturers, and other suppliers. The Medical Devices segment distributes medical devices. The Retail Pharmacy segment operates and franchises a network of retail drug stores. The Other Business segment engages in the production and sale of pharmaceutical products, chemical reagents, and laboratory supplies. The company also rents and manages properties; distributes medical instruments, Chinese herbal medicines, antibiotics, and biological products; and offers information technology development and medicine consultation, investment, goods and technology import and export, business consultation, health consultation, medical consulting, market information consulting and investigation, and convention and exhibition services. In addition, it manages medical project investment, consulting, and technology training activities. The company was founded in 2003 and is headquartered in Shanghai, the People's Republic of China. Sinopharm Group Co. Ltd. operates as a subsidiary of Sinopharm Industrial Investment Co., Ltd.Read More SHTDF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SHTDF Stock News HeadlinesApril 29, 2024 | marketwatch.comSinopharm Group Shares Fall as Higher Costs Cut Into Quarterly ProfitApril 6, 2024 | morningstar.comSinopharm Group Co Ltd ADR X2S1February 21, 2024 | morningstar.comSinopharm Group Co Ltd 01099January 30, 2024 | morningstar.comSinopharm Group Co Ltd X2SNovember 8, 2023 | morningstar.comSinopharm Group Co Ltd SHTDFMay 12, 2023 | msn.comSinopharm Group (HKEX:1099) Price Target Increased by 8.31% to 29.48April 13, 2023 | finance.yahoo.comPfizer signs strategic cooperation pact with China's SinopharmApril 6, 2023 | msn.comWHO chief expects COVID emergency to end this yearMarch 24, 2023 | msn.comChina approves its first mRNA Covid-19 vaccineMarch 22, 2023 | news.yahoo.comChina approves first home-grown mRNA Covid vaccineFebruary 23, 2023 | forbes.comSinopharm GroupJanuary 20, 2023 | news.yahoo.comSinopharm unit gets OK for clinical trials of mRNA COVID vaccineJanuary 20, 2023 | msn.comPharma major Sinopharm gets approval for clinical trials of mRNA Covid-19 vaccineDecember 8, 2022 | reuters.comSinopharm's second Chinese herb shot is potentDecember 2, 2022 | seekingalpha.comVaxxinity says COVID vaccine outperformed Astra and Sinopharm shots as boosterSeptember 28, 2022 | seekingalpha.comMerck in pact with Sinopharm to launch oral COVID-19 therapy in ChinaSeptember 15, 2022 | msn.comSinopharm to boost local COVID vaccine production in AfricaSeptember 7, 2022 | msn.comChina’s Sinovac to test Omicron-targeting vaccines in ChileJuly 27, 2022 | msn.comDaesang to set up joint venture with China Sinopharm InternationalJuly 17, 2022 | seekingalpha.comWeek In Review: Qiming Closes $3.2 Billion For China Healthcare And Technology InvestmentsJuly 4, 2022 | msn.comHong Kong could have 3 Omicron-targeting jabs by end of year, as health expert reveals Sinopharm hopes to make new vaccine available by DecemberJune 27, 2022 | msn.comChina Donates 10 Mil Doses of Sinopharm COVID-19 Vaccines, SyringesJune 22, 2022 | usnews.comSome Omicron Sub-Variants Escaping Antibodies From Sinopharm Shot -Chinese StudyJune 21, 2022 | reuters.comSome Omicron sub-variants escaping antibodies from Sinopharm shot - Chinese studyMay 31, 2022 | msn.comUniversity of Hong Kong, Sinopharm launch city’s first trial for Omicron-targeting vaccine which could be ready in NovemberSee More Headlines Receive SHTDF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sinopharm Group and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Medical Distribution Sub-IndustryN/A Current SymbolOTCMKTS:SHTDF CUSIPN/A CIK1556605 Webir.sinopharmgroup.com.cn Phone86-21-2305-2666FaxN/AEmployees115,959Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio2.71 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Qingming Yu (Age 60)Executive Chairman of the Board Comp: $896.33kMr. Yong Liu (Age 55)President & Executive Director Comp: $866.78kMs. Xiaojuan Li (Age 48)Chief Financial Officer Mr. Yijian Wu (Age 54)Secretary to the Board, Company Secretary & Authorised Representative Key CompetitorsAlfresaOTC:ARHCFArjo AB (publ)OTCMKTS:ARRJFEBOS GroupOTCMKTS:EBOSFGalenicaOTCMKTS:GALNFMcKesson EuropeOTCMKTS:CAKFYView All Competitors SHTDF Stock Analysis - Frequently Asked Questions How have SHTDF shares performed in 2024? Sinopharm Group's stock was trading at $2.49 on January 1st, 2024. Since then, SHTDF stock has increased by 8.4% and is now trading at $2.70. View the best growth stocks for 2024 here. Are investors shorting Sinopharm Group? Sinopharm Group saw a drop in short interest in May. As of May 15th, there was short interest totaling 4,952,400 shares, a drop of 24.2% from the April 30th total of 6,534,900 shares. Based on an average daily volume of 1,700 shares, the days-to-cover ratio is presently 2,913.2 days. View Sinopharm Group's Short Interest. Is Sinopharm Group a good dividend stock? Sinopharm Group (OTCMKTS:SHTDF) pays an annual dividend of $0.26 per share and currently has a dividend yield of 1.11%. The dividend payout ratio is 26.05%. This payout ratio is at a healthy, sustainable level, below 75%. How do I buy shares of Sinopharm Group? Shares of SHTDF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:SHTDF) was last updated on 6/16/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredWho are Nvidia’s Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sinopharm Group Co. Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sinopharm Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.